MOTE Therapeutics Welcomes MaryJane Rafii as Chief Investment and Business Officer
MOTE Therapeutics, a pioneering biotechnology firm focused on developing targeted RNA delivery solutions, has proudly announced the appointment of MaryJane Rafii, PhD, MBA, as its Chief Investment and Business Officer. This strategic move comes as MOTE accelerates the development of its innovative MOBILIZE platform, a technology that aims to enhance RNA delivery beyond the liver.
An Experienced Leader Joins the Team
Dr. Rafii brings over 15 years of global experience as a seasoned business development and capital strategist. Her expertise encompasses mergers and acquisitions, licensing, and fundraising, with significant involvement in operations across various regions including Europe, Asia, and the UAE. As MOTE strives to achieve critical milestones in its developmental journey, Dr. Rafii is tasked with leading the company's fundraising and partnership strategies.
A Pivotal Moment for MOTE
Roc Cui, Chairman of Fapon and Co-Founder of MOTE, stated, "MaryJane brings a proven track record of successfully scaling biotech ventures through smart capital management and strategic collaborations. Her joining our team is crucial as we navigate through this pivotal stage in MOTE's growth trajectory." Dr. Rafii's vast experience is expected to significantly bolster MOTE’s efforts in advancing its groundbreaking research and innovative solutions.
Innovative Technology at the Core
The MOBILIZE platform, developed by MOTE, addresses one of the significant challenges faced in RNA therapies: effective cell-specific delivery. This platform utilizes a modular lipid nanoparticle (LNP) technology that facilitates the targeted delivery of circular RNA (circRNA) and other complex payloads without relying on chemical conjugation. The result is a simple and efficient method for creating nanoparticles that can be tailored for specific therapeutic applications.
Recent Preclinical Achievements
The recent progress in MOTE’s preclinical studies is remarkable, showcasing the platform's potential through several key achievements:
- 80% reduction in liver uptake, enabling enhanced extrahepatic targeting potential.
- Approximately 30% generation of CAR+ CD8+ T-cells from a low single dose administered in non-human primates.
- Successful B-cell depletion using in vivo CAR-T methodology in non-human primates.
- Effective blood-brain barrier crossing delivery observed in CNS murine models.
What's on the Horizon for MOTE?
MOTE is currently in the process of raising over $40 million in Series A funding to further support its IND-enabling work in CAR-T programs addressing both autoimmunity and hematologic cancers. Furthermore, investigator-initiated trials are anticipated to commence in the latter half of the year in select regions. MOTE’s pipeline also extends to tackling disorders related to hematopoietic stem cells and various neurodegenerative conditions.
A Call for Partnerships
Dr. Rafii encourages collaboration, stating, "Our delivery platform is designed to scale and comes with substantial evidence supporting its applicability across various treatments. We're reaching out to potential partners to join us in revolutionizing RNA medicine." This open invitation reflects MOTE's commitment to advancing therapeutic options for patients worldwide.
About MOTE Therapeutics
MOTE Therapeutics is at the forefront of RNA therapeutics, specifically addressing fundamental challenges in nucleic acid medicine. The company aims to deliver RNA payloads, especially circular RNA, to target cells beyond the liver effectively. Through its proprietary platform, MOTE can functionally modify lipid nanoparticles to achieve specific delivery to previously unreachable cell types. This innovation unlocks potential treatments for diseases such as systemic lupus erythematosus, multiple myeloma, plasma cell leukemia, and neurodegenerative disorders.
About Fapon
Fapon is a global leader in the life sciences sector, committed to providing innovative and integrated solutions for diagnostics, biopharma, and biotherapy. With a comprehensive portfolio that includes raw materials, reagents, and inventive instrument platforms, the company has become a key player in the in-vitro diagnostics market. Fapon distinguishes itself through advanced therapeutic technologies and AI-driven insights, contributing to improved global health outcomes.
Investor Relations Contact
For investor inquiries, please reach out to MaryJane Rafii, Chief Investment and Business Officer at MOTE.
Frequently Asked Questions
What is the primary focus of MOTE Therapeutics?
MOTE Therapeutics is mainly focused on developing innovative RNA delivery solutions, particularly emphasizing the targeted delivery of circular RNA to improve therapeutic outcomes.
Who is MaryJane Rafii?
MaryJane Rafii is the newly appointed Chief Investment and Business Officer of MOTE Therapeutics, bringing extensive experience in business development and capital strategy to the role.
What is the MOBILIZE platform?
The MOBILIZE platform is a modular lipid nanoparticle technology designed to enhance the cell-specific delivery of RNA, specifically targeting areas beyond the liver.
What are MOTE's recent achievements?
Recent preclinical studies by MOTE have shown significant advances, including increased T-cell generation and effective delivery across biological barriers.
What are the future prospects for MOTE?
MOTE is actively seeking investment to further develop its programs and is planning clinical trials aimed at tackling various serious health conditions.
